Table 2.
Clinico-pathological parameters of 300 patients with stage I NSCLC after curative resection in regard to the calculated preoperative GPS. Abbreviations: GPS, Glasgow Prognostic Score; BMI, body mass index; COPD, chronic obstructive pulmonary disease; PAD, peripheral arterial disease; CKD, chronic kidney disease; CHD, coronary heart disease; CRP, C-reactive protein.
| Criterion | All Cases | GPS 0 | GPS ≥ 1 | p Value |
|---|---|---|---|---|
| n = 300 (100%) | n = 229 (76%) | n = 71 (24%) | ||
| Age (years; mean) | 66.0 (60.1–72.2) | 65.3 | 68.3 | 0.243 |
| Weight (kg; mean) | 75 (65–85) | 75 | 75 | 0.995 |
| BMI (kg/m2; mean) | 26.2 (23.5–28.6) | 26.3 | 26.1 | 0.865 |
| Gender | ||||
| Male | 187 (62%) | 139 (61%) | 48 (68%) | 0.294 |
| Female | 113 (38%) | 90 (39%) | 23 (32%) | |
| Smoking Status | ||||
| Yes | 199 (66%) | 149 (65%) | 50 (70%) | 0.404 |
| No | 101 (34%) | 80 (35%) | 21 (30%) | |
| COPD | ||||
| Yes | 126 (42%) | 95 (41%) | 31 (44%) | 0.745 |
| No | 174 (58%) | 134 (59%) | 40 (56%) | |
| PAD | ||||
| Yes | 25 (8%) | 19 (8%) | 6 (8%) | 0.967 |
| No | 275 (92%) | 210 (92%) | 65 (92%) | |
| CKD | ||||
| Yes | 17 (6%) | 12 (5%) | 5 (7%) | 0.566 |
| No | 283 (94%) | 217 (95%) | 66 (93%) | |
| CHD | ||||
| Yes | 41 (14%) | 24 (10%) | 17 (24%) | 0.004 |
| No | 259 (86%) | 205 (90%) | 54 (76%) | |
| Alcohol abuse | ||||
| Yes | 136 (45%) | 96 (42%) | 40 (56%) | 0.033 |
| No | 164 (55%) | 133 (58%) | 31 (44%) | |
| Albumin (g/dL) | <0.0001 | |||
| Albumin < 3.5 g/dL | 21 (7%) | 0 (0%) | 21 (30%) | |
| Albumin ≥ 3.5 g/dL | 279 (93%) | 229 (100%) | 50 (70%) | |
| CRP (mg/L) | <0.0001 | |||
| CRP ≤ 10 mg/L | 247 (82%) | 229 (100%) | 18 (25%) | |
| CRP > 10 mg/L | 53 (18%) | 0 (0%) | 53 (75%) | |
| Histology | 0.101 | |||
| Adenocarcinoma | 191 (64%) | 154 (67%) | 37 (52%) | |
| Squamous cell | 95 (32%) | 64 (28%) | 31 (44%) | |
| Adenosquamous | 2 (1%) | 2 (1%) | 0 (0%) | |
| Large cell | 2 (1%) | 2 (1%) | 0 (0%) | |
| Other | 10 (3%) | 7 (3%) | 3 (4%) | |
| Grading | ||||
| G1 | 55 (18%) | 45 (19%) | 10 (14%) | 0.507 |
| G2 | 131 (44%) | 100 (44%) | 31 (44%) | |
| G3 | 114 (38%) | 84 (37%) | 30 (42%) | |
| Tumor size | ||||
| T1a | 116 (39%) | 96 (42%) | 20 (28%) | 0.024 |
| T1b | 78 (26%) | 61 (27%) | 17 (24%) | 0.367 |
| T2a | 106 (35%) | 72 (31%) | 34 (48%) | 0.002 |
| Tumor stage | 0.011 | |||
| IA | 194 (65%) | 157 (69%) | 37 (52%) | |
| IB | 106 (35%) | 72 (31%) | 34 (48%) | |
| Lymphatic invasion | ||||
| Yes | 80 (27%) | 58 (25%) | 22 (31%) | 0.346 |
| No | 220 (73%) | 171 (75%) | 49 (69%) | |
| Vascular invasion | ||||
| Yes | 28 (9%) | 17 (7%) | 11 (15%) | 0.041 |
| No | 272 (91%) | 212 (93%) | 60 (85%) | |
| Surgical procedure | 0.721 | |||
| Lobectomy | 279 (93%) | 214 (93%) | 65 (91%) | |
| Bilobectomy | 8 (3%) | 6 (3%) | 2 (3%) | |
| Sleeve Lobectomy | 11 (4%) | 7 (3%) | 4 (6%) | |
| Pneumonectomy | 2 (1%) | 2 (1%) | 0 (0%) |